Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
The Competition and Markets Authority (CMA) has rejected the remedy proposed by United Health (the bidder) and EMIS to reduce the risks to competition and has announced it is launching a Phase 2 investigation into the acquisition. The bidder and EMIS have confirmed they will proceed with the Phase 2 investigation. Due to the investigation, they have extended the long stop date for the deal and extended the period during which EMIS shareholders will be entitled to dividends by one year.
EMIS Group |
Deal to proceed, pending Phase 2 investigation |
Acquisition update |
Software and comp services |
12 April 2023 |
Share price performance
Business description
Analyst
For the purposes of the Takeover Code, Edison Investment Research is deemed to be connected with EMIS Group. EMIS Group is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||
The Competition and Markets Authority (CMA) has rejected the remedy proposed by United Health (the bidder) and EMIS to reduce the risks to competition and has announced it is launching a Phase 2 investigation into the acquisition. The bidder and EMIS have confirmed they will proceed with the Phase 2 investigation. Due to the investigation, they have extended the long stop date for the deal and extended the period during which EMIS shareholders will be entitled to dividends by one year.
Year end |
Revenue |
PBT* |
Diluted EPS* |
EMIS adj. dil. EPS** (p) |
DPS |
P/E |
12/18 |
149.7 |
33.4 |
40.4 |
45.0 |
28.4 |
40.3 |
12/19 |
159.5 |
41.0 |
53.5 |
51.1 |
31.2 |
30.5 |
12/20 |
159.5 |
43.4 |
56.4 |
50.4 |
32.0 |
28.9 |
12/21 |
168.2 |
43.5 |
55.0 |
55.5 |
35.2 |
29.6 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **EMIS adjusted EPS – cash accounts for development costs and excludes exceptional items and amortisation of acquired intangibles.
On 17 June 2022, the boards of Bordeaux UK Holdings II Limited, an affiliate of Optum UK and a wholly owned subsidiary of UnitedHealth Group (‘Bidco’) and EMIS announced that they had reached agreement on the terms of a recommended all cash offer, pursuant to which Bidco will acquire the entire issued and to be issued ordinary share capital of EMIS for 1,925p per share. The acquisition is being implemented by means of a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.
After a Phase 1 investigation, the CMA announced on 17 March that it had concerns that the merger could affect competition, particularly for population health management and medicines optimisation software. Bidco and EMIS offered legally binding proposals to the CMA to address the concerns identified but on 31 March the CMA confirmed that it had rejected the remedy and has referred the deal to a Phase 2 investigation. On 6 April, Bidco and EMIS confirmed that they intend to proceed with the Phase 2 investigation and will continue to engage constructively and collaboratively with the CMA. With the consent of the Executive of the Panel on Takeovers and Mergers, Bidco and EMIS have agreed to extend the long stop date for completion of the acquisition from 30 June 2023 to 30 June 2024 (subject to the approval of the court). EMIS and Bidco have also agreed to amend and restate the co-operation agreement in connection with their intention to proceed with the Phase 2 investigation, including, among other things, that EMIS shareholders will be entitled to receive an interim dividend for H123 and an interim or final dividend for FY23, in each case of up to 21.3p per share if declared and paid or payable prior to the effective date in accordance with EMIS’s ordinary course financial calendar.
|
|
Research: Metals & Mining
Since our outlook note published on 7 July 2022, Alkane has made several important announcements. Firstly, it improved its FY23 production guidance to 62,000–70,000oz (a 17% increase) after impressive H123 production at Tomingley and now expects to reach the upper end of this range. This has resulted in our EPS forecast for FY23 increasing by 30.6% from A$0.0445/share to A$0.0582/share. This was followed by the approval of the Tomingley Gold Extension Project, permitting open-cut mining at the Roswell and San Antonio deposits (including underground mining at the former), extending the mine life at Tomingley to at least 2031. Additionally, Alkane announced an inferred mineral resource at Kaiser of 4.7Moz AuE (0.48Mt Cu, 2.05Moz Au). Finally, it reported Q323 gold production of 16,641oz, bringing the current year to date production figure to 54,431oz.